Protagonist Therapeutics Receives Consensus 'Buy' Ratings from Nine Firms

Summary

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) has received a consensus ‘buy’ rating from nine brokerages, with an average price target of $67.20. Analysts’ ratings include one hold, seven buy, and one strong buy. Recent price targets have been raised by JMP Securities to $69.00 and HC Wainwright to $80.00. The stock has risen 7.8% recently, with a market cap of $3.82 billion. The company reported a quarterly EPS of ($0.55), missing estimates, and had revenue of $5.55 million. Insiders have sold shares, and institutional investors own 98.63% of the stock.Market Beat

Impact Analysis

This event is at the company level, focusing on Protagonist Therapeutics. The consensus buy rating and increased price targets suggest positive sentiment among analysts, likely boosting investor confidence and potentially driving the stock price upward. The stock’s recent rise of 7.8% indicates immediate positive market reactions to the analyst ratings. However, the missed quarterly EPS and insider selling could pose risks, potentially leading to volatility. Institutional ownership at 98.63% implies strong backing, which might stabilize the stock against insider selling pressures.Market Beat The historical stock movement data shows a mild upward trend, further supporting the positive outlook but caution is advised due to potential fluctuations.